Kevin O'Hayer
Incyte Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin O'Hayer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:52 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03978637 · Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationIncyte Corporation · terminated · Bronchiolitis Obliterans Syndrome · study director
- Ph1NCT03762447 · A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsIncyte Corporation · completed · Solid Tumors · study director
- Ph1/Ph2NCT02959437 · Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)Incyte Corporation · terminated · Solid Tumors, Advanced Malignancies, Metastatic Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:52 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.Cancer Discov · 2022115 citationsRCR 7.0
- Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.Crit Care Med · 202234 citationsRCR 2.1
- Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.Br J Cancer · 202331 citationsRCR 2.4